Do Mood Stabilizers Help With Anxiety

Mood stabilizers are often discussed in the context of managing mood disorders, but their role in treating anxiety is less established. This article explores the limited effectiveness of mood stabilizers for anxiety relief, providing insights into their mechanisms, benefits, and potential side effects. Understanding how these medications work can help individuals make informed decisions about their treatment options. Many people experience anxiety as a debilitating condition that affects their daily lives, and while mood stabilizers may be used in some cases, they are not typically first-line treatments for anxiety. We will delve into the types of mood stabilizers, their impact on brain chemistry, and how they compare to other anxiety treatments. Additionally, we will discuss the services offered by Huntington Beach Mental Health, which include psychiatric medication management tailored to individual needs.

Mood stabilizers are a class of psychiatric medications primarily used to treat mood disorders, such as bipolar disorder. Their use in managing anxiety is not well supported by evidence and is generally limited to cases where anxiety co-occurs with mood instability. These medications work by balancing neurotransmitters in the brain, which are chemicals that transmit signals between nerve cells. By stabilizing mood fluctuations, mood stabilizers can help alleviate mood symptoms, but their direct effect on anxiety symptoms is less clear.

1. Lithium: Often used for bipolar disorder, lithium is not typically prescribed for anxiety but may indirectly reduce anxiety by stabilizing mood swings.
2. Valproate (Valproic Acid): This medication is effective in managing mood disorders and may have some anxiolytic properties, but it is not a primary treatment for anxiety disorders.
3. Lamotrigine: Primarily used for bipolar disorder, lamotrigine is not generally indicated for anxiety treatment.

Mood stabilizers influence brain chemistry by modulating the levels of neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA), rather than primarily serotonin, dopamine, or norepinephrine, which are more directly involved in anxiety regulation. By enhancing the balance of these chemicals, mood stabilizers can help reduce mood symptoms. Their effect on anxiety symptoms is indirect and less well understood. For instance, serotonin modulation is more commonly targeted by antidepressants and anxiolytics.

Research indicates that mood stabilizers are not generally effective as primary treatments for anxiety disorders. They may be used adjunctively in cases where anxiety is part of a broader mood disorder, such as bipolar disorder with comorbid anxiety. Studies specifically supporting mood stabilizers for anxiety relief are limited and inconclusive.

When comparing mood stabilizers to other anxiety medications, such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines, SSRIs and cognitive-behavioral therapy (CBT) remain the first-line treatments for most anxiety disorders. Mood stabilizers may be beneficial for individuals whose anxiety is intertwined with mood disorders but are not considered superior or equivalent to antidepressants or anxiolytics for primary anxiety treatment.

Common side effects of mood stabilizers may include:

1. Weight Gain: Some mood stabilizers, such as valproate, can lead to weight gain, which may be a concern for many patients.
2. Drowsiness: Fatigue and drowsiness are common, especially when starting treatment.
3. Gastrointestinal Issues: Nausea and digestive discomfort can occur in some individuals.

Further research highlights specific mood stabilizers and their varying impacts on patient weight.

Mood Stabilizers & Weight Changes: Valproate, Lamotrigine, Carbamazepine

Valproate has been proven to be associated with weight gain in up to 50% of its users, and can be detected 2–3 months after initiation. Carbamazepine has been proven to have a low risk of weight gain. Lamotrigine and topiramate are associated with weight loss.



Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder, KP Grootens, 2018